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ABSTRACT: The global burden of morbidity and mortality arising from viral infections 
is high; however, the development of effective therapeutics has been slow. As our 
understanding of innate immunity has expanded over recent years, knowledge of natural 
host defenses against viral infections has started to offer potential for novel therapeutic 
strategies. An area of current research interest is in understanding the roles played by 
naturally occurring cationic host defense peptides, such as the cathelicidins, in these innate 
antiviral host defenses across different species. This research also has the potential to inform 
the design of novel synthetic antiviral peptide analogs and/or provide rationale for therapies 
aimed at boosting the natural production of these peptides. In this review, we will discuss 
our knowledge of the antiviral activities of cathelicidins, an important family of cationic host 
defense peptides, and consider the implications for novel antiviral therapeutic approaches.
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The global burden of morbidity and mortality arising from viral infections is high and there is an 
unmet need for the development of effective therapeutics. Current therapies are generally expen-
sive, highly virus specific (requiring early viral identification) and can have a narrow window in 
disease progression during which application is required for clinical efficacy. These factors, and 
the pandemic threat posed by the possible emergence of new strains (e.g., influenza and novel 
coronaviruses), highlight the urgent need for novel broader-spectrum antiviral intervention strate-
gies. Our advancing knowledge of innate host defenses against viral infection may hold the key to 
developing novel therapeutic approaches. The antiviral potential of naturally occurring cationic 
host defense peptides (CHDPs; also known as antimicrobial peptides) has recently received increas-
ing attention, with interest in both the direct microbicidal and immunomodulatory properties of 
these peptides. In addition to enhancing our understanding of the roles CHDPs play in defense 
against viral infection, this research has the potential to inform the design of novel synthetic 
antiviral peptide analogs and/or provide the rationale for therapies aimed at boosting the natural 
production of these peptides. 
Cationic host defense peptides
CHDPs constitute a critical component of the innate immune system [1] with both microbicidal 
properties and the potential to modify inflammation and immunity [2]. These small, positively 
charged peptides are conserved throughout evolution across vertebrates and invertebrates, with the 
two major families in mammals being cathelicidins and defensins. The broad-spectrum bactericidal 
potential of certain CHDPs has provided the primary focus for the field, with interest in their 
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development as therapeutics for bacterial infec-
tions, either as an alternative or complementa-
tion to antibiotics. However, there is a relative 
paucity of research on the nature and scope of 
the antiviral properties of these peptides, regard-
ing both the direct virucidal potential and the 
capacity to modify the outcome of viral infec-
tion through modulation of inflammation and 
immunity. A number of studies now suggest 
that CHDPs, including cathelicidins, may play 
important roles in host defense against viral 
infection and be significant in the development 
of novel therapeutic strategies.
In addition to their direct microbicidal 
activities, cathelicidins and defensins have 
demonstrated pleiotropic immunomodulatory 
and inflammomodulatory potential [3,4]. The 
relative significance of any direct microbicidal 
properties versus these modulatory roles in host 
defense against infection remains unclear, but 
is of increasing interest. These peptides may 
consequently offer the potential to inform the 
development of novel therapeutics that target 
both the microbe and the nature and magnitude 
of the innate and adaptive immune responses. 
Indeed, the latter approach may be of particular 
importance with regard to avoiding the rapid 
development of resistant strains. However, 
despite this undoubted potential of CHDPs, 
mechanistic studies are still in their infancy, 
particularly with regard to antiviral properties. 
This review seeks to examine the potential of 
cathelicidins as antiviral agents and the extent to 
which their capacity to modulate inflammation 
and immunity may be relevant in this regard.
Cathelicidins
Cathelicidins are defined by the presence of an 
N-terminal signal sequence, a conserved cathelin-
like domain and a variable C-terminal domain, 
which becomes the mature functional peptide 
upon proteolytic cleavage. The cathelin-like 
domains have high sequence homology to cathe-
lin, a porcine leukocyte protein belonging to the 
cystatin family of cysteine protease inhibitors. 
However, the cathelin-like domain of the sole 
human cathelicidin hCAP-18 has recently been 
shown to have no cysteine protease inhibitory 
function [5]. The mature cathelicidin peptides 
range from 12 to 88 amino acids and, in relative 
contrast to the defensins, show great diversity 
across species; from proline-rich structures and 
disulfide bond-stabilized b-hairpins, to linear 
peptides, which form amphipathic a-helices 
upon interaction with lipid membranes [6]. Thus, 
although classified as the ‘cathelicidin family’, 
this diversity raises questions regarding the func-
tional conservation between the mature catheli-
cidin peptides of different species. Furthermore, 
whereas humans, mice, rats and rabbits express 
only a single cathelicidin, other species, such a 
pigs and cows, express multiple, more divergent 
cathelicidins. This review will focus primarily on 
human CAP-18 (hCAP-18), murine CRAMP 
(mCRAMP) and porcine cathelicidins.
Human cathelicidin
In humans, the cathelicidin hCAP-18 is encoded 
by the CAMP gene on chromosome 3p21.3. 
hCAP-18 is primarily found in the specific gran-
ules of neutrophils and is cleaved extracellularly 
by proteinase-3 [7] to produce LL-37, a linear, 
37-amino acid peptide with two leucine residues 
at the N-terminus, as the dominant cleavage 
product. In addition, hCAP-18/LL-37 can be 
synthesized and released by epithelial cells in an 
inducible manner and can be detected in a broad 
range of body fluids, including airway surface 
liquid (via bronchoalveolar lavage), sweat, saliva, 
semen, milk and vernix caseosa (the sebum-rich 
substance that covers the skin of a newborn 
human baby [2]). Leukocytes such as macro-
phages, eosinophils, lymphocytes and, to a lesser 
extent, mast, NK, B and T cells, can also express 
this peptide [8]. The LL-37 peptide was initially 
characterized to be a-helical in structure [9], and 
full mapping by 3D nuclear magnetic resonance 
has revealed a curved amphipathic helix with 
a disordered C-terminus [10]. Although LL-37 
peptide is the major mature cleavage form, alter-
native fragments can also be generated by serine 
proteases (e.g., kallikreins) in keratinocytes and 
sweat [11,12]. In addition, an ALL-38 form can 
be generated by gastricin cleavage in semen [13]. 
Studies have also demonstrated that smaller, 
naturally occurring and synthetic LL-37 frag-
ments can act as immunomodulatory molecules 
[14]. LL-23, a 23-mer fragment representing the 
N-terminus amino acid sequence of LL-37, has 
been shown to induce production of MCP-1 in 
human monocytic cells [15], and a partial 22-mer 
fragment of the C-terminus of LL-37 has been 
shown to induce secondary necrosis of apoptotic 
human neutrophils [16]. The capacity to modify 
the balance of microbicidal and immunomodu-
latory properties [14] illustrates the potential to 
manipulate peptide function in the development 
of potential therapeutic peptides.
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The inducible expression of hCAP-18 is subject 
to complex transcriptional and post-transcriptional 
control and is upregulated in response to infec-
tious and inflammatory signals and wounding 
[17–20]. Recent studies have also demonstrated 
the importance of 1,25-dihydroxyvitamin D3 
activity on the CAMP gene promoter [21–24] and 
implicated a role for parathyroid hormone in the 
regulation of this cathelicidin [25]. In addition, 
research has identified compounds such as butyr-
ate as having therapeutic potential as inducers of 
cathelicidin expression [26].
hCAP-18 is found at approximately 1.2 µg/ml 
in plasma, at least partly complexed with 
lipoproteins, under normal physiological 
concentrations [27]. This is estimated to be 
approximately 20% of the amount present in 
circulating neutrophils, with approximately 
600 ng per 106 cells. However, under inflam-
matory conditions, neutrophil degranulation 
and induction of hCAP-18 expression by epi-
thelial and other cells leads to an increase in 
the concentration in inflamed organs, with 
an approximate threefold increase in lung 
lavage levels of hCAP-18 reported in infants 
with pulmonary or systemic infections [28]. 
Although challenging to extrapolate, this sug-
gests airway surface liquid levels in the region 
of 20 µg/ml. Levels are also found to be raised 
in cystic fibrosis lung disease [29], and the 
expression of hCAP-18 is higher in eosinophils 
from asthmatics than controls [30]. hCAP-18/
LL-37 has been found at very high levels (a 
median 1.7 mg/ml) in the skin of patients with 
psoriasis [31], where LL-37 has, in fact, been 
proposed to contribute to disease pathogenesis 
[32]. It is important to note that most estimates 
of in vivo cathelicidin concentration do not 
distinguish between the uncleaved hCAP-18 
precusor and the cleaved active LL-37, which 
may be critical in determining functional 
sequelae.
The importance of hCAP-18/LL-37 to host 
defense is indicated by the increased suscepti-
bility to infection (particularly periodontal) in 
individuals with the rare condition morbus Kost-
mann [33]. In this severe congenital neutropenia, 
neutrophils can be restored by treatment with 
recombinant granulocyte-colony stimulating fac-
tor; however, these cells (but not epithelial cells) 
are deficient in hCAP-18. In addition, hCAP-18/
LL-37 levels are clearly associated with altered 
susceptibility to infection in human dermatologi-
cal pathologies [34]. Furthermore, overexpression 
of the human cathelicidin LL-37 in murine lungs 
enhanced the clearance of the opportunistic 
respiratory pathogen Pseudomonas aeruginosa 
[35], demonstrating the potential for therapeu-
tic applicability in vivo. However, despite fairly 
broad-spectrum bactericidal activity in vitro, 
LL-37 has limited activity at the peptide con-
centrations characterized in vivo (particularly at 
epithelial surfaces) when studied under physi-
ologically relevant cation conditions (review in 
[4]). In addition, the bactericidal properties of 
LL-37 can be inhibited by serum apolipoprotein 
[36], DNA and F-actin [37]. It is unclear as to what 
extent these caveats also extend to antiviral func-
tions. However, these issues raise the question of 
whether cathelicidins are primarily microbicidal 
agents in vivo, or have antimicrobial effects via 
more indirect mechanisms.
In addition to their antimicrobial potential, 
cathelicidins have been demonstrated to have mul-
tiple roles in the modulation of inflammation and 
immunity, most of which are unaffected by cation 
concentrations. These are extensive and beyond 
the scope of this review, but are described in detail 
elsewhere [4]. These properties include, but are 
not limited to, modulation of cytokine release, 
induction of angiogenesis and wound healing, 
endotoxin neutralization, modulation of dendritic 
cell differentiation and function, properties as 
chemokines and adjuvants, and the capacity to 
modulate cell death (Box 1). LL-37 has this very 
broad array of properties by virtue of its capacity 
to directly interact with key innate immune effec-
tor cells, including monocytes and macrophages, 
dendritic cells, lymphocytes, epithelial cells and 
neutrophils. Although many of these functions 
are not fully mechanistically defined, a range of 
different receptors are implicated. These include 
FPR2 (also known as FPRL-1) [38–40], CXCR2 
[41], MrgX2 [42], P2X7R [43] and GAPDH [44]. 
Furthermore, some immunomodulatory proper-
ties of cathelicidins have been demonstrated to 
be retained by the d-enantiomers, suggesting 
that they are not mediated by standard receptor-
dependent mechanisms [14,45,46]. Where these 
modulatory functions have the capacity to signifi-
cantly skew the host response to infection, such 
properties would be expected to have considerable 
potential, both in the context of bacterially and 
virally mediated diseases.
Murine cathelicidin
In mice, the cathelicidin mCRAMP is encoded 
by the Camp gene on chromosome 9. The 
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murine protein maintains 52% amino acid 
sequence identity with hCAP-18 and porcine 
cathelicidin PR-39 in the cathelin-like domain, 
and 80% identity with each individually [47]. 
Full-length mCRAMP is cleaved to produce the 
active 34 amino acid, 5-kDa C-terminal peptide 
[48] with a tertiary structure, which was deter-
mined by NMR to be two amphipathic a-helices 
connected by a flexible region [49]. mCRAMP 
demonstrates similar expression patterns and 
functions to its human ortholog [47], is stored in 
neutrophil granules and is expressed in an induc-
ible manner in epithelial cells and leukocytes 
[50–55]. However, unlike hCAP-18, expression of 
the Camp gene is not regulated by vitamin D [22].
Mice deficient in mCRAMP (Camp-/-) have 
normal fetal development and fertility, and dem-
onstrated no obvious phenotype when housed 
under aseptic barrier-controlled conditions [50]. 
However, these Camp-/- mice have increased 
susceptibility to bacterial infections in multiple 
organ systems. These phenotypes include dimin-
ished protection against necrotic skin infection 
caused by Group A Streptococcus [50], delayed 
clearance of P. aeruginosa infection in the cornea 
[56] and lung [53], increased susceptibility to intes-
tinal infection with the murine enteric pathogen 
Citrobacter rodentium [51], increased susceptibil-
ity to urinary tract infection with Escherichia coli 
[52] and increased susceptibility to pulmonary 
infection with Klebsiella pneumoniae [53]. These 
phenotypes clearly demonstrate the critical, 
nonredundant role for murine cathelicidin in 
host defense against bacterial infection. How-
ever, despite evidence of microbicidal proper-
ties against relevant pathogens in vitro [47,50,51,53], 
the extent to which physiological concentrations 
of mCRAMP are directly microbicidal in vivo 
remains unknown. In addition, mCRAMP 
has also been demonstrated to have modula-
tory properties [40,57] that could have key roles 
in vivo. Finally, recent studies [46,58], discussed 
later in this review, also indicate key roles for 
cathelicidins in murine antiviral defenses.
Porcine cathelicidins
Pigs express a diverse group of cathelicidins with 
varying structural motifs and activities. These 
include five different protegrins (PGs), three 
a-helical peptides (PMAP-23, -36 and -37), two 
prophenins (PF-1 and -2) and the PR-39 peptide 
[59]. The mature peptides derived from the por-
cine cathelicidins are structurally very different; 
however, the PMAP peptides are a-helical (and 
more similar to LL-37 and mCRAMP), PR-39 
and the prophenins are proline-rich helical pep-
tides, and the PGs are arginine- and cysteine-rich 
b-sheet peptides.
The PGs were first identified in 1993 [60] and 
are between 16 and 18 amino acids in length. Five 
distinct isoforms (PG-1–5) are presently known, 
identified through purification (PG-1, PG-2 and 
PG-3) and cDNA cloning (PG-4 and -5). As with 
cathelicidins in other species, PGs are synthesized 
and stored as inactive propeptides in neutrophil 
granules, but are proteolytically cleaved into active 
products in the extracellular environment, which, 
in the case of PGs, is by neutrophil elastase [61].
PGs possess a unique and well-defined two-
stranded b-sheet structure in solution, joined by 
a b-hairpin loop, and with four conserved cysteine 
residues forming disulfide linkages, stabilizing the 
peptide and facilitating interaction with biological 
membranes and enabling pore-forming activity. 
Investigations into the PG mechanism of anti-
microbial action has identified that disruption of 
bacterial plasma membranes is one of their impor-
tant properties [62,63]. However the folding of PGs, 
controlled by structural disulfide bridging, was 
not found to be essential for antimicrobial activity, 
but was required for permeabilization of biologi-
cal membranes [64], raising interesting questions 
regarding the critical events in antimicrobial activ-
ity. PGs also have significant lipopolysaccharide 
Box 1. Immunomodulatory and inflammomodulatory properties of LL‑37.
 ● Modulation of cellular responses to RNA/DNA [32,39,150–152,155,158,167]
 ● Modulation of cellular responses to other inflammatory stimuli [14,43,147,148,168–171]
 ● Modulation of dendritic cell differentiation and function [32,161,172,173]
 ● Chemotaxis of neutrophils, eosinophils, monocytes, memory T cells and mast cells [38,40,41,57,174–176]
 ● Modulation of neutrophil function [55,159]
 ● Induction of mast cell degranulation [177]
 ● Modulation of cell death [16,160,178–185]
 ● Angiogenesis [186,187]
 ● Wound healing and cell proliferation [45,188–192]
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(LPS) binding and neutralization activity [65] and 
have been shown to reduce the LPS-mediated 
induction of TNF release from monocytic cell 
lines [66]. In addition, unlike other cathelicidins 
and many defensins, PGs are particularly resistant 
to physiologically relevant salt-sensitive inhibi-
tion of their antimicrobial activity [67], making 
them attractive templates for the development of 
synthetic antimicrobial compounds.
The therapeutic potential of induced or exoge-
nous synthetic PG peptides has been investigated 
in vitro in a number of studies. While each of 
the PGs have been demonstrated to have micro-
bicidal activity to some extent, the 18 amino 
acid PG-1 peptide has demonstrated the broad-
est antimicrobial activity over a wide range of 
Gram-positive and -negative organisms, fungi 
and yeasts. PG-1 has been shown to have activ-
ity against the elementary bodies of Chlamydia 
trachomatis through membrane permeabilization 
[68,69] and significant activity against Mycobacte-
rium tuberculosis (up to 99% reduction in CFUs) 
has been confirmed in vitro [70]. Other bacteria 
such as Neisseria gonorrhoeae and Pseudomonas 
also have demonstrable and significant suscepti-
bility to membrane damage and killing as a result 
of PG exposure [71,72]. In addition, the yeast phase 
of Candida albicans is also susceptible to PG-1, 
-2, -3 and -5, but not to PG-4 [73].
Despite these promising in vitro studies, evi-
dence of protective effects in infectious disease 
models in vivo remains minimal. In one study, 
ectopic expression of PG-1 in transgenic mice 
was found to confer enhanced resistance to infec-
tion with Actinobacillus suis, a pathogen associ-
ated with porcine pneumonia, septicemia and 
abortion [74]. Exogenous PG-1 was also shown to 
prevent P. aeruginosa colonization of inoculated 
porcine skin wounds, and decreased bacterial 
counts in established skin infections [75]. Interest-
ingly, PGs have also been proposed as potential 
antitumor agents through their cytotoxic activity 
on mammalian tumor cells [76,77], although the 
selectivity of the lytic activity towards malig-
nant cells remains unknown. The extent to 
which these in vivo effects result primarily from 
microbicidal activity or may be due to immuno-
modulatory properties remains unclear, and the 
antiviral potential of PGs is largely undeveloped.
The cathelicidins PMAP-23, PMAP-36 and 
PMAP-37, named for their varying lengths 
[78,79], are expressed by porcine myeloid cells. 
The amphipathic a-helical conformation of 
these peptides has been hypothesized to be the 
key mechanism by which PMAP molecules can 
integrate into biological membranes [79]. This 
subgroup of peptides has been demonstrated 
to have potent antibacterial, antifungal and 
anti nematodal activity against organisms that 
include Caenorhabditis elegans [80] and C. albi-
cans [81]. However, little is known regarding their 
activity towards viral pathogens.
PR-39 is a 39-amino acid porcine cathelici-
din that is rich in proline and arginine residues 
and has a significant multifunctional reper-
toire of antibacterial and immunomodulatory 
activities that include modulation of cell death 
pathways [82], wound healing properties [83] and 
chemotactic activity [6,84,85]. The peptide has a 
poly-l-prolinehelixal structure, enabling it to 
integrate into and cross biological membranes 
[86], and it is relatively resistant to proteolytic 
degradation in biological f luids, a property 
attributed to its high proline content [87]. Simi-
lar to other cathelicidins, PR-39 is primarily 
neutrophil-derived and is upregulated at sites 
of infection and inflammation. Little is known 
about the antiviral activity of this peptide, 
although a number of studies have demonstrated 
significant antibacterial activity against a range 
of organisms. However, rather than direct lytic 
activity, PR-39 is thought to act through stereo-
specific interactions with intracellular targets, 
as indicated by differences in the activity of the 
d-enantiomer of the PR-39 peptide [88].
With a similar poly-l-proline helical structure 
to PR-39, PF-1 and PF-2 are two variants, with 
79- and 80-amino acid residues respectively, 
which can be distinguished either by an extra 
pyroglutamic acid or with a glutamine residue. 
Prophenins and prophenin derivatives have dem-
onstrated significant activity against a variety of 
bacterial species [89,90], but their antiviral activity 
remains undetermined.
Cathelicidins from other species
Cathelicidins have been characterized in multi-
ple different species, including (but not restricted 
to) rabbits, cows, horses, sheep, monkeys and 
fish (the reader is referred to other publications 
for further information on these peptides [91–96]). 
Although not within the primary remit of this 
review, it is worth noting the extensive body of 
research characterizing the bovine cathelicidins. 
These were among the first cathelicidin peptides 
to be identified in mammals [97–100]. Similarly to 
pigs, cows possess multiple unique neutrophil-
derived cathelicidins with considerable structural 
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variability, including indolicidin, Bac5 and Bac7, 
the 12-amino acid bovine dodecapeptide and 
BMAP-27, BMAP-28 and BMAP-34. Indeed, 
studies have indicated the presence of 11 distinct 
cathelicidin genes in cattle [101]. These bovine 
peptides have well-characterized antibacterial 
activity [91], with BMAP-28, indolicidin and the 
Bac5/Bac7 peptides demonstrating significant 
bacterial membrane binding and/or disrupting 
properties [102–104]. Indolicidin has also recently 
been shown to reduce parasitic sporozoite infec-
tivity and viability [105]. In addition, bovine cat-
helicidins also have a range of complementary 
properties, with BMAP-28 capable of modu-
lating inflammatory gene expression in macro-
phages [106,107] and apoptosis in Leishmania para-
sites [108], and reducing lethality in murine mod-
els of sepsis [109], while indolicidin  is capable of 
inhibiting LPS-induced TNF but inducing che-
mokine production in vitro [110]. The presence 
of cathelicidins across diverse species attests to 
their importance, while their variability, perhaps 
resulting from the diverse microbial challenges 
these species face, represents a valuable resource 
in the development of novel therapeutics.
Antiviral properties of cathelicidins
Research on the antiviral properties of CHDP 
dates back to the discovery of these peptides 
and is most prominent in the study of defen-
sins (reviewed in [111]). However, this area has 
been significantly under-researched and, until 
recently, the antiviral properties of cathelicidins 
had received little attention, despite their bacteri-
cidal potential, pleiotropic immunomodulatory 
and inflammomodulatory properties, regulation 
by inflammatory stimuli and the existence of 
genetically modified Camp-/- mice. Neverthe-
less, a number of recent studies conducted in 
humans, mice and in vitro have stimulated this 
field and suggest that cathelicidins may prove 
to be significant to host defense against viral 
infections (Table 1).
Vaccinia virus
Vaccinia virus (VV) is an enveloped poxvirus 
utilized in the vaccination against smallpox 
infection and its eradication. Infection with VV 
is normally asymptomatic or may cause a mild 
rash. However, individuals with atopic dermatitis 
(AD) have a predisposition to the development of 
a serious, disseminated rash, called eczema vacci-
natum, in response to smallpox vaccination [112]. 
The expression of hCAP-18 and b-defensins is 
reduced in AD, and has been proposed to be 
involved in the increased predisposition to skin 
infections in these patients [34]. These observa-
tions raised the possibility that these peptides 
may play a role in preventing eczema vaccina-
tum. Consistent with this hypothesis, expres-
sion of LL-37 was found to be induced by VV 
exposure in normal and psoriatic skin biopsies, 
but not in those from AD skin [113]. Address-
ing this initially in cell culture-based studies, 
both LL-37 and mCRAMP were demonstrated 
to have antiviral properties against VV (~1 log 
decrease at 25 µM) by inducing VV envelope 
damage [58]. Further research demonstrated 
that LL-37 removed the outer membrane of VV 
in a manner consistent with the carpet model 
for peptide-mediated membrane disruption, 
but did not damage the inner membrane [114]. 
Table 1. Antiviral effects of cathelicidins.
Virus Genome Capsid/family Antiviral activity
Vaccinia virus DNA Enveloped poxvirus Viral envelope damage (LL‑37)
Exposure of new antigens (LL‑37)
More pox lesions in Camp-/- mice (mCRAMP)
RSV RNA Enveloped 
paramyxovirus
Antiviral when premixed with virus (LL‑37)
Protective effects on epithelial cells (LL‑37)
Influenza RNA Enveloped 
orthomyxovirus
Binds virus/membrane disruption (LL‑37)
Protection in infected mice (LL‑37 and mCRAMP)
Decreased cytokines in infected mice (LL‑37)
HIV RNA Enveloped lentivirus Suppression of HIV reverse transcriptase (LL‑37)
HSV DNA Enveloped 
herpesvirus
Antiviral in vitro (LL‑37 and protegrin‑1)
Dengue RNA Enveloped flavivirus Inhibition of dengue serine protease (protegrin‑1)
Adenovirus DNA Nonenveloped 
adenovirus
Antiviral in vitro (LL‑37)
mCRAMP: Murine CRAMP; RSV: Respiratory syncytial virus.
Antiviral potential of cathelicidins REviEW
future science group www.futuremedicine.com 61
Interestingly, loss of the outer membrane resulted 
in viral susceptibility to antibody neutralization 
owing to exposure of antigens that are normally 
sequestered under the envelope [114]. The oppor-
tunity for in vivo mechanistic studies represented 
by Camp-/- mice then enabled the demonstration 
of the antiviral effects of cathelicidins in vivo, 
with mCRAMP-deficient mice developing sig-
nificantly more pox skin lesions than controls 
following infection with VV [58]. Thus, these 
studies clearly demonstrate a nonredundant, 
direct, antiviral host defense role for cathelicidins 
against VV infection.
Respiratory syncytial virus
Respiratory syncytial virus (RSV) is the most 
common viral pathogen causing acute lower 
respiratory tract infection in young children 
worldwide [115], and is a leading cause of mor-
bidity and mortality in infants, the elderly and 
immunocompromised individuals. It has also 
been implicated in the later development of 
asthma [116]. There is currently no vaccine or 
effective antiviral treatment for RSV [117] and 
novel therapeutics are required. Airway epithe-
lial cell expression of LL-37/hCAP-18 is induced 
in vitro by RSV infection [118], suggesting a pos-
sible role in host defense. Interestingly, this 
upregulation was further enhanced in the pres-
ence of the 1:25 OH metabolite of vitamin D, 
raising the possibility of a role for seasonal vita-
min D insufficiency in innate antiviral defenses. 
A recent evaluation of children presenting with 
RSV bronchiolitis also discovered significantly 
lower levels of hCAP-18 expression in the serum 
of those with RSV bronchiolitis than in chil-
dren presenting with bronchiolitis induced by 
human rhinovirus infection [119]. In addition, 
lower than median hCAP-18 levels in RSV-
infected children were found to correlate with 
more prolonged hospitalization. Furthermore, 
our recent data demonstrate that LL-37 has 
effective antiviral activity against RSV in vitro, 
retained by a truncated central peptide frag-
ment [120]. LL-37 prevented virus-induced cell 
death in epithelial cultures, significantly inhib-
ited the production of new infectious particles 
and diminished the spread of infection, with 
antiviral effects observed whether the peptide 
was premixed with viral particles or used to pre-
treat the epithelial cells. These data implicate 
hCAP-18/LL-37 as an important, targetable 
component of the innate host defense against 
RSV and suggest future potential in strategies 
aimed at prophylactic modulation of cathelicidin 
expression in vulnerable individuals and/or the 
development of synthetic peptide analogs for use 
in postexposure prophylaxis.
Influenza A virus
In addition to RSV, LL-37 has antiviral effects 
against another common respiratory viral patho-
gen; influenza A virus (IAV). Infection with 
IAV is a significant cause of morbidity, and is 
responsible for 2000–6000 deaths per year in 
the UK, with >30,000 deaths in the 1989–1990 
epidemic [121]. Globally, the H1N1 pandemic in 
2009 was estimated to have caused over 200,000 
respiratory deaths [122]. Although vaccination 
can help protect vulnerable individuals against 
prevalent subtypes, new emergent strains repre-
sent a global pandemic threat, and the potential 
for the emergence of resistance to neuraminidase 
inhibitors (the current first-line therapy) is of 
serious concern. Interestingly, maintenance of 
serum 25-OH vitamin D levels over autumn 
and winter months in the northern hemisphere 
has been found to reduce the incidence of acute 
viral respiratory tract infections [123] and a small 
prospective clinical trial in Japan suggested that 
vitamin D3 supplementation during the winter 
could significantly reduce the incidence of IAV 
infection in children [124]. These studies raised 
the possibility that vitamin D-regulated cathe-
licidin expression could have a role in influenza 
susceptibility. We subsequently demonstrated 
that human and murine cathelicidins have anti-
viral effects against IAV, both in vitro and in vivo 
[46]. LL-37 and mCRAMP, but not PG-1, dem-
onstrated antiviral properties when preincubated 
in vitro with IAV (~1 log decrease at 10 µg/ml 
against A/PR/8/34 [H1N1], but somewhat less 
effective against A/Udorn/307/72 [H3N2]). A 
recent publication went on to demonstrate that 
LL-37 can bind directly to IAV [125]. Although 
maximal in vitro antiviral activity required 
preincubation of the peptide and virus, antivi-
ral properties were also observed with peptide 
addition delayed until after viral infection of 
the cells, and even after the cells were treated 
with peptide and then washed before infec-
tion [125]. Surprisingly, LL-37 was found not to 
alter the binding or initial uptake of virus by 
cells, but electron microscopic evaluation dem-
onstrated peptide-mediated disruption of viral 
membranes, suggested to impair viral survival 
or propagation within the infected cells [125]. We 
demonstrated therapeutic cathelicidin-mediated 
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protection against infection in a murine model, 
using an aerosolized therapeutic regimen of 
LL-37 or mCRAMP administration, consist-
ing of a preinfection dose and daily administra-
tion for a week after infection [46]. These treat-
ments resulted in significantly greater survival 
and less weight loss compared with control IAV 
infected animals. The efficacy of this regimen 
was similar to treatment with aerosolized zana-
mavir (a neuraminidase inhibitor currently used 
in humans) in this model. In addition to some-
what lower viral loads, the animals treated with 
LL-37 demonstrated strikingly lower levels of 
inflammatory lung cytokines. This observation 
raises the possibility that inflammomodulatory 
properties could be fundamental to the protec-
tion against systemic illness and lethality, irre-
spective of virucidal properties. Interestingly, 
the d-enantiomers of LL-37 and mCRAMP 
were similarly protective, but scrambled con-
trol peptides had no activity, indicating that the 
effects of these cathelicidins are probably more 
dependent upon amphipathicity than overall 
charge. The lack of protective effects in mice 
treated with PG-1, suggests species specificity, 
but the very different structural characteristics 
of this peptide must be noted when interpreting 
these data.
HIV
HIV is the lentiviral causative agent of AIDS. 
Infection with HIV has been radically trans-
formed over the last two decades, from a fatal 
disease to a manageable chronic infection, by 
the development and successful use of anti-
retroviral drugs that can inhibit multiple steps 
in the viral lifecycle [126]. However, continued 
drug development is necessary to combat the 
emergence of drug-resistant strains. Initial 
observations with host defense peptides and 
synthetic analogs suggested antiviral potential 
against HIV, with varying 50% inhibitory con-
centration (IC
50
) estimates of 1–4 µg/ml [127]. 
Subsequent research, utilizing a lentiviral vec-
tor to consider peptide inhibitory potential in 
the early stages of the replication cycle, demon-
strated dose-dependent LL-37- and PG-medi-
ated inhibition of lentiviral vector transfection 
(with IC
50
 of ~30 and ~16.8 µg/ml, respectively) 
[128]. Although the inhibition of vectors con-
taining the HIV-1 envelope required higher 
concentrations of LL-37 [128], this cathelicidin 
and its derivative fragments were also later dem-
onstrated to inhibit the replication of HIV-1 
isolates in primary CD4+ T cells and cell lines 
[129,130], with the action of LL-37 independent 
of HIV-1 receptor expression alteration in these 
cells. A more recent study also demonstrated 
that LL-37 could suppress HIV reverse tran-
scriptase activity in a dose-dependent man-
ner and that this function was retained by a 
central fragment of the peptide (amino acids 
17–32) [131]. In addition, the bovine peptides 
BMAP-18 and indolicidin have been shown to 
have anti-HIV activity in vitro [130,132]. These 
studies suggest promise for anti-HIV activity 
of cathelicidins; however, clinical studies are 
somewhat less clear. Constitutive expression 
of hCAP-18 has been demonstrated in human 
epididymal epithelium and attached to sperma-
tozoa in seminal plasma [133] and hCAP-18 is 
also expressed in cervicovaginal secretions [134]. 
This expression of hCAP-18 is upregulated in 
cervicovaginal secretions from individuals with 
bacterial sexually transmitted infections [134]. 
In addition, expression levels in cervico vaginal 
secretions from HIV-negative individuals who 
were in HIV serodiscordant relationships were 
highest in those whose HIV-positive partners 
had the highest viral load [135]. Furthermore, 
HIV-1 neutralizing activity was demonstrated in 
the cationic peptide fraction of the cervicovagi-
nal secretions and could be further enhanced 
by the addition of recombinant LL-37. These 
data suggest that upregulation of cathelicidin 
expression in response to HIV exposure may 
provide a degree of protection from HIV infec-
tion. However, HIV-1 neutralizing activity of 
the cervicovaginal secretions was not found 
to correlate with the detected levels of endog-
enous LL-37 [135], and increased expression of 
hCAP-18/LL-37 has also been correlated with 
increased HIV acquisition in Kenyan sex work-
ers [134]. Although the latter observation could 
be a consequence of a higher prevalence of sexu-
ally transmitted infections in those individuals 
acquiring HIV, the in vivo significance of LL-37 
expression in protection against HIV infection 
remains to be determined.
HSV
The first evidence for antiviral properties of 
CHDP came during the earliest character-
ization of the properties of a-defensins, with 
the demonstration of direct antiviral activity 
of HNP-1 against the enveloped virus HSV-1 
[136]. This was shown to be dependent upon 
both pH and temperature, and to be inhibited 
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by the presence of serum. Despite further 
studies on the antiviral effects of defensins on 
this virus, the activity of cathelicidins is less 
well characterized. One study demonstrated 
antiviral activity of LL-37 against HSV-1 
(~2 log decrease) in vitro using A549 cells, 
but used very high concentrations of peptide 
(500 µg/ml; ~100 µM) in this study [137] and 
the mechanisms of action were not explored 
experimentally. Another study also described 
antiviral activity against strains of HSV-1 and 
HSV-2, with 30–50% protection in a quanti-
tative microplate screening assay at 44.5 µM 
LL-37, using ME-180 cells [138]. A similar mag-
nitude of protection was described for PG-1 
using the same assay (40–70% protection at 
92.8 µM). Strikingly, the PG-1 d-enantio-
mer demonstrated increased antiviral activity 
against HSV-1 and -2, whereas removal of the 
intramolecular disulfide bonds inactivated the 
peptide [138]. In addition, the bovine peptides 
indolicidin and BMAP-28 (but not BMAP-27) 
have been shown to have some antiviral activity 
against HSV-1 and/or HSV-2 [138–140].
Dengue virus
Dengue is the most prevalent mosquito-borne 
viral infection of humans. Dengue virus, an 
RNA virus that is part of the Flaviviridae fam-
ily, has four major serotypes (DENV-1 to-4), 
and can result in a number of clinical syn-
dromes including dengue fever, dengue shock 
syndrome and dengue hemorrhagic fever. A 
total of 50–100 million instances of dengue 
fever are estimated to occur annually and effec-
tive therapeutics or vaccines for the dengue virus 
are lacking.
A recent study demonstrated that PG-1 could 
inhibit DENV-2 serotype replication in MK2 
cells (at IC
50
 of 11.7 µM) in vitro at concentra-
tions that were shown to be of low toxicity to the 
cells [141]. PG-1 had a highly effective capacity 
to inhibit dengue serine protease NS2B-NS3pro 
in vitro. NS2B-NS3pro is responsible for the 
cleavage of viral polyproteins to produce struc-
tural and nonstructural proteins, and inhibition 
of this activity has inhibitory effects on dengue 
virus replication. Whether this effect extends to 
cathelicidins from other species, such as humans, 
remains to be determined.
Nonenveloped viruses
All of the antiviral properties of cathelicidins 
described above have been against enveloped 
viruses, with viral envelope disruption impli-
cated as the mechanism of action in the case 
of VV and IAV [58,114,125]. In addition, viral 
envelope disruption has been described in a 
substantial proportion of the reports evaluating 
the antiviral activities of defensins (reviewed in 
[111]). However, defensins have also been found 
to have antiviral activity against adenovirus (Ad) 
in a serotype-dependent manner by inhibiting 
an early step in viral entry [142]. The extent to 
which cathelicidins are active against nonenvel-
oped viruses remains largely unstudied. Whereas 
expression of retrocyclin (cyclical q-defensin) 
analogs in the chloroplasts of tobacco plants 
conferred resistance against Tobacco Mosaic 
Virus, expression of functional PG-1 failed to 
do so [143]. Nevertheless, one group has dem-
onstrated LL-37 activity against Ad19 (~2 log 
decrease at 500 µg/ml LL-37) [137]. These data 
demonstrated slower antiviral kinetics when 
compared with activity against HSV, perhaps 
implicating a different mode of action against 
nonenveloped viruses. By contrast, the same 
study found no significant activity against Ad3, 
Ad5 or Ad8 [137]. However, our preliminary, 
previously unpublished studies, suggest LL-37 
activity against Ad5 at more physiological pep-
tide concentrations, demonstrating significant 
inhibition of cellular transfection with Ad5–
GFP after 1-h preincubation at ≥10 µg/ml LL-37 
peptide (Figure 1). While these studies need to 
be extended, and definitive, mechanistic studies 
remain to be performed on a range of nonenvel-
oped viruses, our preliminary data and the peer-
reviewed, published research suggest that cat-
helicidins have antiviral properties that extend 
beyond damaging viral envelopes.
Mechanisms & immunomodulation
The mechanisms underpinning the antivi-
ral properties of cathelicidins remain largely 
unknown (Figure  2). The in vitro studies 
described above for VV, RSV and IAV all 
suggest that direct interaction with the viral 
particle may be one possible antiviral mecha-
nism [58,114,120,125] and optimal effectiveness is 
generally shown following pretreatment of the 
virus with peptide, prior to infection of cells. 
However, the effects on nonenveloped viruses 
indicate additional mechanisms of antiviral 
activity. It is interesting to note that antivi-
ral activity was also observed when cells were 
treated with peptide and then washed before 
infection with the virus [120,125]. This might be 
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an effect of peptide retained on the cell surface 
or internalized by the cells. Indeed, we have 
previously demonstrated that LL-37 can inter-
act with epithelial membranes and be actively 
internalized in a microtubule-dependent man-
ner [144]. Furthermore, membrane-associated 
human b-defensin-2 has been shown to desta-
bilize the RSV envelope during cell entry by the 
virus [145] and the retrocyclin RC2 can crosslink 
and immobilize surface glyco proteins to block 
influenza hemagglutinin-mediated fusion of 
the viral and endosomal membranes during 
viral internalization [146]. These precedents for 
the antiviral properties of CHDP being medi-
ated via interactions with the cell membrane 
suggest a need to evaluate such mechanisms 
for cathelicidins. However, alternatively, the 
effects observed after peptide treatment of the 
cells could represent the induction of an antivi-
ral state resulting from the immunomodulatory 
properties of these peptides. Indeed, the dra-
matic effects of LL-37 on cytokine production 
and survival in IAV-infected mice, compared 
with the relatively modest effect on viral loads 
in vivo [46], also suggest that peptide-mediated 
modulation of inflammation and immunity 
may be an important component of their anti-
viral function.
Cathelicidins have a broad repertoire of 
inflammomodulatory and immunomodula-
tory activities, which might be expected to 
affect viral infection and the host response. 
In relation to LL-37-mediated antibacte-
rial defenses, this peptide has antiendotoxic 
properties resulting from its lipopolysac-
charide binding capacity [147]. However, in 
addition, we demonstrated that LL-37 can 
modulate downstream signaling and actually 
induce certain chemokines while also inhib-
iting proinflammatory cytokine production 
[147]. Indeed, further work has subsequently 
demonstrated that this peptide has a com-
plex interaction with Toll-like receptor (TLR) 
signaling pathways [148–152], with the poten-
tial to modify the nature of host responses to 
viral  and bacterial infection. Interestingly, 
these effects are observed at peptide concen-
trations that are lower (typically 1–5 µg/ms) 
than those required for microbicidal activity. 
Mammalian cells respond to a range of dif-
ferent microbial components or pathogen-
associated molecular patterns via innate pat-
tern recognition receptors including TLR, 
RIG-I-like receptors and nucleotide-binding 
domain leucine-rich repeat containing recep-
tors (reviewed in [153]). Antiviral responses 
depend, at least in part, on TLR recognition 
of the viral genome, with ssRNA and dsRNA 
viruses recognized by TLR7/8 and TLR3 and 
viral DNA by TLR9 [154]. Thus, the ability of 
cathelicidins to modulate cellular responses to 
TLR-3, -7, -8 and -9 agonists [32,39,150–152,155] 
may be of considerable significance, although 
some of the literature remains contradic-
tory. LL-37 has been shown to enhance viral 
dsRNA signaling via TLR3 [150], colocaliz-
ing with TLR3 and dsRNA and promoting 
cytokine responses in rhinovirus-infected 
human airway epithelial cells and activated 
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Figure 1. Antiviral activity of LL‑37 against adenovirus. A total of 2 × 106 plaque‑
forming units Ad–GFP (E1‑deleted, replication‑deficient adenovirus encoding GFP; 
ViraQuest Inc., IA, USA) was preincubated for 1 h at 37°C over a concentration range 
of either LL‑37 or scrLL‑37 prior to addition of this virus and peptide mix to A549 
cells at a multiplicity of infection of 100. Alternatively, A549 cells were preincubated 
for 1 h over a concentration range of LL‑37 (0–50 µg/ml) before removal of the 
media containing the peptide, washed twice with phosphate‑buffered saline, and 
media containing 2 × 106 plaque‑forming units of Ad–GFP was added to the cells, 
resulting in a multiplicity of infection of 100. In all cases, treated cells were then 
incubated in phenol‑red free Dulbecco’s modiﬁed Eagle’s medium supplemented 
with 1% Ultroser™ G serum substitute (Pall Biopharmaceuticals, France) at 37°C, 5% 
CO2 for 18 h before the fluorescence intensity of each well was measured using a 
BioTek® (Bedfordshire, UK) multiwell plate reader. Figure shows mean fluorescent 
intensity as a percentage of untreated transfected cells ± standard error of the 
mean, from n ≥ 5. 
*p < 0.01; **p < 0.001. 
Ad–GFP: GFP‑expressing adenovirus; scr: Scrambled.
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peripheral blood mono nuclear cells. LL-37 
was also shown to promote IL-8 release by a 
human airway epithelial cell line in response 
to polyinosinic–polycytidylic acid, a synthetic 
analog of dsRNA [151]. However, by contrast, 
LL-37 and mCRAMP have been reported to 
complex with polyinosinic–polycytidylic acid 
and inhibit TLR3 binding and signaling in 
APCs [152]. A recent study demonstrated that 
LL-37 upregulated dsRNA-induced TLR3 
responses in human cells, but downregu-
lated these responses in murine cells, with 
mCR AMP downregulating the responses 
in cells from both species [39]. Although the 
authors proposed that this represents species 
specificity, the human and murine cell lines 
used in this study were not ideally matched, 
raising the possibility that the nature of the 
responses may alternatively depend upon the 
cell lineage studied (e.g., leukocytes vs epi-
thelial cells). LL-37 has been known for some 
time to be capable of transferring nucleic acids 
into mammalian cells [156]. This may underpin 
the enhanced response to nucleic acids, given 
the intracellular location of their sensors. 
However, it is also possible that nucleic acids 
complexed with cathelicidin may elicit modi-
fied responses through the additional involve-
ment of LL-37 receptors, such as FPR2, or the 
engagement of different trafficking pathways 
[39]. Indeed, otherwise nonimmunogenic self-
DNA and self-RNA has also been shown to 
induce TLR-7, -8 and -9-dependent inflam-
matory responses when complexed with LL-37 
[32,155,157]. This has been shown to lead to the 
induction of type I interferons from dendritic 
cells, monocytes [32,155,157] and keratinocytes 
[158]. If a similar effect should occur in response 
to viral nucleic acids complexed to cathelicidin, 
this could potentially underpin the induction 
of an enhanced antiviral state in response to 
peptide exposure. Although clearer mecha-
nistic studies are required, and the effect of 
cathelicidins upon RIG-I-like receptors and 
nucleotide-binding domain leucine-rich repeat 
containing receptors pathways needs to be 
determined, these processes may play a key role 
in cathelicidin-mediated antiviral responses.
In addition to their capacity to modulate 
pattern recognition receptor signaling path-
ways and cytokine responses, additional modu-
latory properties of cathelicidins may modify 
host responses to viral infections. These include 
chemotactic properties that could influence the 
nature and magnitude of the cellular inflam-
mation response [38], the ability to modify 
neutrophil function [55,159] and the capacity to 
promote apoptosis in infected epithelial cells 
[160]. We have also demonstrated that LL-37 
can induce the secondary necrosis of apop-
totic neutrophils and the release of neutrophil 
granules proteins [16]. This might be expected 
to result in an increase in viral exposure to 
neutrophil a-defensins, which also have anti-
viral properties against a range of pathogenic 
human viruses (reviewed in [111]). Finally, in 
addition to altering dendritic cells responses to 
viral nucleic acids, we have shown that LL-37 
can modulate the differentiation and function 
of these cells, with the capacity to alter the 
nature and magnitude of subsequent adaptive 
immune responses [161]. In that context, it is 
interesting to note that the weight loss observed 
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Figure 2. Possible mechanisms of cathelicidin‑mediated antiviral activity. The 
mechanisms underpinning cathelicidin‑mediated antiviral activity remain largely 
undefined. However, studies suggest that these peptides may modulate infection 
with different viruses in a number of different ways, as indicated by the green 
boxes. 
PRR: Pattern recognition receptor.
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in IAV-infected mice largely stabilized in the 
LL-37-treated infected animals around the 
time of adaptive immune response onset [46], 
raising the possibility that the nature of this 
response was altered. The extent to which any 
of these mechanisms are fundamental to cat-
helicidin-mediated antiviral activity remains 
to be determined. Never theless, the capacity 
of these peptides to modulate recognition of 
viral pathogen-associated molecular patterns, 
downstream inflammatory signaling, innate 
cellular responses, cell death and adaptive 
immunity, make their modulatory properties 
of clear interest in the development of novel 
antiviral therapeutic strategies.
Conclusion & future perspective
The discovery of novel approaches to prevent 
and treat viral diseases remains a significant 
challenge for the medical and scientific com-
munities. Recent developments in our under-
standing of key naturally occurring innate 
antimicrobial agents, immune recognition 
and signaling offer new opportunities to target 
critical components of antiviral host defenses. 
New insights into the antiviral potential of 
CHDPs, such as cathelicidins, suggest that 
these peptides may be important targetable 
components of this antiviral defense system 
and may additionally represent templates to 
inform the development of novel synthetic 
antiviral analogs.
The evidence that cathelicidins have key 
antiviral roles is only just starting to emerge; 
however, the antiviral potential of other CHDPs 
is already more clearly established [111]. Natu-
rally occurring a- and b-defensins have activ-
ity against IAV, RSV, HIV, HPV, HSV and 
Ad in vitro, and in various in vivo models of 
infection with some of these viruses. In addi-
tion, synthetic analogs based on q-defensins 
(not expressed in humans due to a premature 
stop codon [162]) have shown promise, includ-
ing in a murine model of severe acute respira-
tory syndrome infection [163]. Similarly to the 
studies with cathelicidins, research conducted 
using defensins suggests that peptides may tar-
get the virus directly, affect multiple different 
points in the viral lifecycle and also modu-
late innate immune signaling and the nature 
and/or magnitude of the inflammatory and 
immune responses to infection. It is tempting 
to speculate that the diversity of mechanisms 
reported for different peptides may represent 
many facets of the innate host defense, target-
ing the same virus simultaneously via multiple 
different approaches by utilizing a range of 
different peptides. With that in mind, it may 
be important that future approaches study the 
synergy between peptides, rather than exam-
ine them only in isolation. It is also possible 
that the capacity of CHDPs to modulate the 
nature and magnitude of host defense responses 
against infection may offer the potential to 
develop therapeutics with broader applicabil-
ity against multiple viruses and minimize the 
potential to promote the emergence of resistant 
strains by avoiding direct peptide targeting of 
the virus. Indeed, the recent development of 
innate defense regulator peptides, initially engi-
neered to remove direct antibacterial activity 
while retaining antimicrobial function, is dem-
onstrating promise against a range of infectious 
diseases [164–166]. Such peptides hold exciting 
potential as future therapeutics and may also 
be applicable to viral infections.
The extent to which CHDPs may prove to 
be maximally efficacious given therapeutically, 
used for postexposure prophylaxis or targeted 
in an entirely prophylactic manner (such as 
aiming to enhance native peptide production 
via winter season vitamin D administration) 
remains to be determined. The effective target-
ing of such approaches will be dependent upon 
the development of an enhanced understanding 
of the mechanisms by which these peptides have 
antiviral effects, the extent to which these are 
directly virucidal or via modulation of the innate 
immune system, and the physiological relevance 
of in vitro observations in animal models and 
human disease. Although this research is at an 
early stage, the potential for the development 
of novel interventions targeting viruses and the 
innate host responses to these pathogens has 
clear appeal.
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EXECUTivE SUMMARY
Cationic host defense peptides
 ● Cationic host defense peptides (CHDPs) are critical components of the innate immune system.
 ● CHDPs have broad‑spectrum antibacterial potential and the capacity to modify inflammation and immunity.
 ● CHDPs are emerging as antiviral components of innate immune responses with possible therapeutic potential.
Cathelicidins
 ● Cathelicidins (e.g., human CAP‑18/LL‑37, murine CRAMP and porcine protegrins/PMAPs/prophenins/PR39) are 
multifunctional CHDPs.
 ● Cathelicidins are expressed primarily by neutrophils, epithelial cells and macrophages.
 ● Cathelicidin expression can be regulated by vitamin D metabolites and can be upregulated by vitamin D and/or 
phenyl butyrate.
 ● Cathelicidins have nonredundant roles in defense against infection in multiple systems in vivo.
Antiviral activity of cathelicidins
 ● Cathelicidins have antiviral activity against vaccinia virus, respiratory syncytial virus, influenza virus, HIV, HSV, 
dengue virus and adenovirus.
 ● The mechanisms of antiviral activity include direct damage to viral envelopes, inhibition of viral protein function 
and modulation of host cell responses to infection.
Future perspective
 ● Evaluating the antiviral potential of cathelicidins and the direct and indirect mechanisms involved is at an early stage.
 ● Innate immune defense may involve synergies between multiple CHDPs acting via different mechanisms.
 ● CHDP‑mediated modulation of host defense responses against viral infection may have therapeutic potential 
with broader applicability against multiple viruses and may minimize the potential to promote the emergence of 
resistant strains by avoiding direct peptide targeting of the virus.
 ● Targeting upregulation of endogenous CHDP expression (e.g., via winter season vitamin D administration) may be a 
prophylactic antiviral strategy.
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